Corporate Profile for Bayer Biotechnology, dated April 16, 1999.--(BUSINESS WIRE)-- The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: April 16, 1999
Company Name: Bayer Corporation
Pharmaceutical Division
Biotechnology
Address: 800 Dwight Way
Berkeley, CA 94710
USA
Main Telephone
Number: 510/705-5000
Internet Home
Page Address
(URL) www.bayerpharma-na.com
Chief Executive
Officer: Wolf-Dieter Busse, PhD
Senior Vice President, Biotechnology
Chief Financial
Officer: Robert Montag
Investor Relations
Contact: Laura L. Rohde
Business number: 510/705-7881
Home number: 510/705-7891
Public Relations
Contact: Laura L. Rohde
Business number: 510/705-7881
Home number: 510/705-7891
Industry: Biotechnology, Pharmaceuticals
-0- Company description: Bayer Biotechnology, located in Berkeley California, is the Worldwide Biotechnology Center for Bayer Corporation's Pharmaceutical Division. The Biotechnology Center is responsible for the discovery, development, and process development of recombinant protein recombinant protein Molecular biology A protein encoded by recombinant DNA or generated from a recombinant gene. See Recombinant pharmacology. drugs and gene-based therapies for asthma, cancer, chronic obstructive pulmonary disease chronic obstructive pulmonary disease n. Abbr. COPD A chronic lung disease, such as asthma or emphysema, in which breathing becomes slowed or forced. , diabetes mellitus diabetes mellitus Disorder of insufficient production of or reduced sensitivity to insulin. Insulin, synthesized in the islets of Langerhans (see Langerhans, islets of), is necessary to metabolize glucose. In diabetes, blood sugar levels increase (hyperglycemia). , multiple sclerosis multiple sclerosis (MS), chronic, slowly progressive autoimmune disease in which the body's immune system attacks the protective myelin sheaths that surround the nerve cells of the brain and spinal cord (a process called demyelination), resulting in damaged areas , and osteoporosis osteoporosis (ŏs'tēō'pərō`sĭs), disorder in which the normal replenishment of old bone tissue is severely disrupted, resulting in weakened bones and increased risk of fracture; osteopenia . Development projects include Kogenate 3, and improved recombinant recombinant /re·com·bi·nant/ (re-kom´bi-nant) 1. the new entity (e.g., gene, protein, cell, individual) that results from genetic recombination. 2. pertaining or relating to such an entity. See also under DNA. Factor VIII factor VIII n. A factor in the clotting of blood, a deficiency of which is associated with hemophilia A. Also called antihemophilic factor, antihemophilic globulin, antihemophilic globulin A, , and IL-4RA, which may help prevent asthma. Bayer's current emphasis is on building strategic alliances and partnerships to broaden the base of potential products. Bayer Corporation is a research-based company with major businesses in health care and life sciences and chemicals. The company had 1998 sales of $8.1 billion and employs more than 23,000 people. Bayer Corporation is investing $15 billion in capital expenditures and research and development from 1995 through the year 2004. 1999 capital investment and R&D expenditures are projected to total $1.6 billion. Bayer Corporation, with headquarters in Pittsburgh, is a member of the worldwide Bayer Group, a $31 billion chemicals and health care group based in Leverkusen, Germany. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion